Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Company News For May 22, 2019
by Zacks Equity Research
Companies In The News Are: KSS,AZO,HD,MRK
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Merck's Keytruda Fails in Late-Stage Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AbbVie's Brain Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
by Kinjel Shah
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
by Zacks Equity Research
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
4 Dow Stocks to Buy on the Dip Despite Market Volatility
by Nalak Das
After an impressive bull run in the first four months of this year, it seems volatility is once again ready to rear its ugly face in Wall Street.
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
by Zacks Equity Research
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
What's in Store for Affimed (AFMD) This Earnings Season?
by Zacks Equity Research
Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Merck, Charter Communications, Anthem and Norfolk Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Merck, Charter Communications, Anthem and Norfolk Southern
Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Merck (MRK) and Charter Communications (CHTR).
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress
by Swarup Gupta
The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.